Sign in

You're signed outSign in or to get full access.

T. Michael Glenn

Chairman of the Board at Lumen TechnologiesLumen Technologies
Board

About T. Michael Glenn

T. Michael Glenn, 69, is Lumen’s independent, non‑executive Chairman of the Board (since May 2020) and has served as a director since 2017. He is a former President & CEO of FedEx Corporate Services and longtime FedEx executive, bringing deep experience in market development, customer operations, communications, and strategic execution; he also served as a Senior Advisor at Oak Hill Capital Partners and currently sits on Pentair PLC’s board as chair of its Compensation Committee . The Board has affirmatively determined his independence (all directors except the CEO), and he leads quarterly executive sessions of independent directors .

Past Roles

OrganizationRoleTenureCommittees/Impact
FedEx Corp.President & CEO, FedEx Corporate Services; EVP Market Development & Corporate Communications; SVP Worldwide Marketing/Customer Service for FedEx Express1981–2016Member of five‑person Executive Committee; led strategic business activities and market development
Oak Hill Capital PartnersSenior Advisor2017–2020Private equity advisory experience augmenting capital markets perspective

External Roles

OrganizationRoleSinceCommittee/Position
Pentair PLCIndependent Director2017Chair, Compensation Committee

Board Governance

  • Roles: Independent, non‑executive Chairman; HRCC member. As Chairman, Glenn presides over Board/independent director meetings, sets agendas with the CEO, ensures information quality and timeliness, represents the Board in stakeholder communications, and oversees Board functioning .
  • Independence: Board affirmed independence for all nominees other than the CEO; HRCC membership meets heightened independence requirements .
  • Committees: Human Resources & Compensation (HRCC) member; HRCC met 6 times in 2024 with 100% attendance; independent directors met in executive session quarterly led by the Chairman .
  • Attendance: In 2024, there were 28 total Board/committee meetings; each director attended more than 90% of Board and respective committee meetings; all then‑current directors attended the 2024 annual meeting .

Fixed Compensation

Component (2024)Amount/Detail
Annual Cash Retainer$100,000
Chairman Supplemental Fee$200,000
Committee Fee – HRCC Member$17,500
Fees Earned or Paid in Cash (reported)$317,500
Stock Awards (grant date fair value)$204,773
Other Compensation$5,000 (annual physical exam reimbursement)
Total (reported)$527,273
2024 Equity Grant Units157,518 RSUs (time‑vested; annual grant; directors may defer into RSUs)
2024 Equity VestingOne‑year cliff vest from May 16, 2024 grant date (vests May 16, 2025; accelerated in limited circumstances)

Notes:

  • Director compensation comprises cash retainers/committee fees and an annual time‑vested equity grant targeted at $200,000; HRCC reviewed director pay and made no changes in May 2024, determining it was near the 50th percentile vs peers .
  • Dividends/dividend equivalents on director awards accrue and are subject to the same vesting terms; Lumen paid no dividends in 2024 .

Performance Compensation

FeatureDisclosure
Performance‑based metrics for director payNone; outside director equity awards are time‑vested only (no options/PSUs, no performance metrics disclosed for directors)
Extraordinary service feesAllowed at discretion; none paid in 2024

Other Directorships & Interlocks

CompanyRoleCommittee/PositionInterlock/Conflict Notes
Pentair PLCIndependent DirectorChair, Compensation CommitteeWithin Lumen’s “no more than three other boards” guideline; no HRCC interlocks/insider participation disclosed for 2024 at Lumen
  • HRCC Interlocks: No HRCC member was an officer/employee of Lumen or subsidiaries; no Lumen executive officer served on the board of any company employing any Lumen director in 2024 .
  • Related Party Transactions: None reportable under Item 404 for 2024 .

Expertise & Qualifications

  • Strategic leadership in market development, customer operations, and communications; contributes to Board skills in sales/marketing, strategy, governance/stakeholder alignment, and HR leadership .
  • Board leadership: As Chairman, Glenn organizes Board activities, agendas, and information flow, and presides over shareholder meetings, enhancing Board effectiveness and oversight .

Equity Ownership

CategoryShares/UnitsNotes
Unrestricted Shares Beneficially Owned199,362Includes 77,143 held indirectly in a trust
Unvested Restricted StockNo unvested restricted stock; Glenn uses RSUs when deferring
Unvested RSUs (as of 12/31/2024)157,518Annual director grant (time‑vested)
Vested Deferred Stock Units307,318Deferred under Non‑Employee Directors Deferred Compensation Plan
Percent of Class<1%As of record date
Director Stock Ownership Guideline5x annual cash retainer ($500,000)Guideline; director must reach within 5 years
Compliance StatusIn complianceAs of March 19, 2025 (Glenn among compliant directors)
Hedging/PledgingProhibitedInsider trading policy prohibits hedging/pledging by directors and Section 16 officers

Governance Assessment

  • Strengths: Independent, non‑executive Chairman with explicit Board leadership responsibilities; HRCC member meeting heightened independence standards; high engagement with more than 90% attendance and quarterly executive sessions; director pay aligned near market 50th percentile; meets 5x retainer ownership guideline; no related‑party transactions or hedging/pledging allowed .
  • Watchpoints: Dual compensation governance exposure (chairing Pentair’s comp committee while serving on Lumen’s HRCC) can raise optics of pay benchmarking drift even absent disclosed interlocks; continued chair rotation policy suggests potential leadership transition considerations over time, though Board may extend service if in Company’s best interest .
  • Overall: Governance signals support investor confidence—independence, attendance, ownership alignment, and transparent compensation practices—while external comp chair role warrants ongoing monitoring for any peer selection/target percentile shifts (no adverse findings disclosed) .